Image by National Cancer Institute



We are developing a portfolio of protein degrader candidates designed to address genetic drivers of disease. Assets discovered via our proprietary AI-driven AutoDx platform are designed and optimized to be novel disease-modifying therapeutic candidates. These programs chart the development and enablement milestones required to execute a clear and efficient path to advance candidates into clinical development. Our mission is to provide a disease-modifying therapy for patients with unmet clinical need.